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1. Introduction 
Protein C is a vitamin K–dependent zymogen, discovered in 1976 in bovine plasma (Stenflo, 
1976). It is derived from the human PROC gene on chromosome 2 (2q13-q14) which contains 
9 exons (Rezaie, 1993). Post-translational modifications include -hydroxylation at Asp71, 
N-linked glycosylation at residues 97, 248, 313 and 329 and Ǆ-carboxylation of 9 glutamic 
acid residues which forms the Gla domain at the amino terminus. Human protein C is 62kD 
protein and consists of 419 amino acids. The four major moieties that make up the protein C 
molecule are a Gla domain, two epidermal growth factor (EGF)- like regions, a small 
activation peptide, and an active serine protease domain (Griffin, 2005). Mature 62 000 Da 
human protein C is cleaved by a furin-like endoprotease that releases Lys156–Arg157 before 
secretion from liver cells. Protein C is activated on the endothelial surface when thrombin 
binds to thrombomodulin and cleaves protein C’s activation peptide. This conversion to 
activated protein C (APC) is augmented by endothelial cell protein C receptor (EPCR) 
(Fukudome & Esmon, 1994). Protein C circulates in plasma at 70 nM whereas APC is present 
in much lower concentrations (40 pM  or ~ 2.3 ng/mL) (Gruber & Griffin, 1992).   
APC was  first recognized as an anticoagulant. In the presence of its cofactor, protein S, APC 
degrades the coagulation factors Va and VIIIa and inhibits thrombin generation. The light 
chain provides anticoagulant activity by having highly specific protein–protein interactions 
with factors Va and VIIIa followed by proteolytic inactivation of factor Va by cleavage at 
Arg (506) and Arg (306) and of factor VIIIa by cleavage at Arg (336) and Arg (562) (Zlokovic 
& Griffin, 2011). In addition, APC promotes fibrinolysis by binding to plasminogen activator 
inhibitor which prevents inhibition of plasminogen conversion to plasmin. The significance 
of APC as an anticoagulant is reflected by the findings that deficiencies in protein C result in 
severe familial disorders of thrombosis (Baker & Bick, 1999). Replenishment of protein 
C/APC in patients with systemic or local hypercoagulation can reverse the abnormality.   
2. Anti-inflammatory and cytoprotective functions of APC 
In addition to its anticoagulant activity, APC exerts a broad range of cytoprotective  and 
anti-inflammatory actions described below.  
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2.1 Inflammation 
Independent of its effect on coagulation, APC has potent anti-inflammatory properties 
(Joyce, 2001; Mosnier & Griffin, 2003) associated with a decrease in pro-inflammatory 
cytokines and a reduction of leukocyte recruitment. Joyce et al (Joyce, 2001) have shown that 
APC directly suppresses expression of p50 and p52 nuclear factor (NF)-B  subunits in 
human umbilical vein endothelial cells. The NF-B pathway is important for the expression 
of a wide variety of inflammatory genes including tumor necrosis factor (TNF)-ǂ and cell 
adhesion molecules that are associated with diseases ranging from inflammation to cancer 
(Li & Verma, 2002). Direct inhibition of NF-B is sufficient to block symptoms of many 
inflammatory diseases so these inhibitors have potential therapeutic value (Bell, 1915; Li & 
Verma, 2002; Calzado, 1914; Calzado, 2007). APC inhibits the expression and activation of 
NF-B in unstimulated and stimulated monocytes (White, 2000; Xue, 2007; Yuksel, 2002), 
keratinocytes (Xue, 2004), endothelial cells (Franscini, 2004). APC also suppresses 
inflammation in vivo by inhibition of NF-B (Cheng, 2006). In addition, APC has the ability 
to upregulate and activate matrix metalloproteinase (MMP)-2 (Nguyen, 2000; Xue, 2004), a 
MMP with anti-inflammatory properties (Itoh, 2002; McQuibban, 2002) and to suppress 
gelatinase B  (Cheng, 2006; Xue, 2007), a MMP associated with many inflammatory 
conditions (Itoh, 2002; Ram, 2006). During acute inflammation, plasma APC levels are 
diminished (Liaw, 2004) and inflammatory cytokines such as interleukin (IL)-1ǃ and TNF-ǂ, 
as well as endotoxin, can attenuate thrombomodulin and EPCR expression which further 
reduces the ability of endothelial cells to generate APC. Acute inflammation is exacerbated 
in mice genetically predisposed to a severe protein C deficiency (Lay, 2007).  
APC also regulates the immuno/inflammatory response. Monocytes treated with APC 
decrease the release of tissue factor (Toltl, 2008), the pro-inflammatory cytokines TNF-ǂ 
(Grey, 1994), IL-1ǃ, IL-6, and & IL-8 (Stephenson, 2006). Additionally, APC induces the 
release of the anti-inflammatory cytokine IL-10 from monocytes (Toltl, 2008). 
APC targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice (Kerschen, 
2010).  Expression of EPCR in mature murine immune cells is limited to a subset of CD8+ 
conventional dendritic cells.  Adoptive transfer of splenic CD11chiPDCA-1- dendritic cells 
from wild-type mice into animals with hematopoietic EPCR deficiency restored the 
therapeutic efficacy of APC, whereas transfer of EPCR-deficient CD11chi dendritic cells or 
wild-type CD11chi dendritic cells depleted of EPCR+ cells did not. These data reveal an 
essential role for EPCR and PAR1 on hematopoietic cells, identify EPCR-expressing 
dendritic immune cells as a critical target of APC therapy, and document EPCR-
independent anti-inflammatory effects of APC on innate immune cells. 
2.2 Cell proliferation and apoptosis 
APC induces growth of cultured human umbilical vein endothelial cells (HUVEC) (Uchiba, 
2004). In smooth muscle cells, APC elicits an increase in [(3)H]-thymidine incorporation 
(Bretschneider, 2007) and enhances proliferation and migration of human skin keratinocytes 
(Xue, 2005). Consistent with the stimulatory effects on cell growth, APC displays strong 
anti-apoptotic properties. APC decreases sepsis-induced apoptosis resulting from increased 
p21 and p53 proteins in mice (Sakar, 2007) and modulates Bcl-2 and Bax and inhibits 
caspase-3 and -8  activity which results in inhibition of apoptosis in a number of cell types 
(Joyce, 2001). During hypoxic stress of brain endothelial cells, APC inhibits p53, reduces pro-
apoptotic Bax and maintains levels of protective Bcl-2 protein, thereby preventing the 
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stimulation of the intrinsic apoptotic pathway (Cheng, 2003). In human skin keratinocytes, 
APC prevents cell apoptosis via inhibition of caspase-3 activation (Xue, 2004) and in 
podocytes, APC protects against  glucose-induced apoptosis both in vitro and in vivo 
(Isermann, 2007). APC inhibits bisphosphonate-induced endothelial cell death via EPCR-
induced inactivation of caspase-3 and NF-κB, and also suggests that APC has the potential 
to be a therapeutic drug in various vascular diseases induced by endothelial cell damage 
(Seol, 2011). 
2.3 Barrier stabilization 
Endothelial cells normally form a dynamically regulated stable barrier at the blood-tissue 
interface, and breakdown of this barrier is a key pathogenic factor in inflammatory 
disorders, such as sepsis. APC boosts the barrier via at least two different mechanisms.  
First, APC enhances sphingosine-1-phosphate (S-1-P) production, which signals through its 
G-protein coupled receptor to stabilize the cytoskeleton and reduce endothelial permeability 
(Feistritzer & Riewald, 2005; Finigan, 2005). Second, APC utilizes the angiopoietin 
(Ang)/Tie2 axis to promote endothelial barrier function (Minhas, 2010). APC significantly 
up-regulates gene and protein expression of Tie2 and Ang1 in a dose (0.01-10 µg/ml) and 
time (0.5 h – 24 h) dependent manner in HUVEC, whilst it markedly inhibits Ang2 with an 
IC50 of ~ 0.1 µg/ml. HUVEC permeability, measured using Evans blue dye transfer, is 
significantly reduced in the presence of APC and, in concordance, the tight junction 
associated protein, zona occludens (ZO)-1, is up regulated and localized peripherally 
around cells, compared to control. Smooth muscle cell migration towards APC-stimulated 
HUVEC is elevated compared to unstimulated cells. Blocking antibodies and small 
interfering (si) RNA treatment, compared to isotype or scrambled siRNA controls, show that 
APC requires three receptors, endothelial protein C receptor (EPCR), protease activated 
receptor (PAR)-1 and Tie2 to perform all these barrier stabilization functions (Minhas, 2010). 
We have shown that HUVEC produce protein C that acts through novel mediators to 
enhance their own functional integrity (Xue, 2010). When endogenous protein C or its 
receptor, EPCR, is suppressed by si RNA, HUVEC proliferation is decreased and apoptosis 
elevated. Interestingly, protein C or EPCR siRNA significantly increases HUVEC 
permeability, which occurs via a reduction of the Ang1/Ang2 ratio and inhibition of the 
peripheral localization of the tight junction protein, ZO-1. In addition, protein C or EPCR 
siRNA inhibits type IV collagen and MMP-2, providing the first evidence that protein C 
contributes to vascular basement membrane formation (Xue, 2010). Barrier stabilization is 
more effective when APC is derived endogenously and functions in an autocrine manner, 
than when the source of APC is exogenous (Feistritzer, 2006). 
The barrier protective effect of APC is also relevant to epidermal keratinocytes (Xue, 2011).  
In response to APC, Tie2, a tyrosine kinase receptor, is rapidly activated within 30 minutes, 
and relocates to cell-cell contacts. APC also increases junction proteins ZO-1, claudin-1 and 
VE-cadherin. Inhibition of Tie2 by its peptide inhibitor or small interfering RNA abolished 
the barrier protective effect of APC (Xue, 2011).   
3. APC cellular signalling  
APC exerts its anti-inflammatory, cyto-protective and barrier stabilization effects by acting 
on receptors which initiates cellular signaling, as described below. 
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3.1 EPCR and PARs 
Many of the cyto-protective actions of APC are mediated through EPCR, which itself is 
anti-inflammatory (Esmon, 2004). This receptor binds protein C and APC with similar 
affinity (Fukudome & Esmon, 1994), and protein C can be converted to APC whilst 
remaining bound to EPCR. EPCR is a type I transmembrane protein which shares 
homology with the major histocompatibility class 1/CD1 family of proteins involved in 
the immune response. EPCR was discovered on endothelial cells, however EPCR was 
subsequently found on some leukocytes (Esmon, 2004) and is strongly expressed by the 
basal layer of keratinocytes in skin epidermis as well as in cultured keratinocytes (Xue, 
2005). Recent studies show that EPCR has important physiological functions. For example, 
over-expression of EPCR protects transgenic mice from endotoxin-induced injury (Li, 
2005) and EPCR is essential for normal embryonic development as deletion of the EPCR 
gene in mice is lethal by embryonic day 10 (Gu, 2002).  
Recently, EPCR has been identified as a marker of certain stem cells in mice (Balazs, 2006; 
Kent, 2009).  EPCR is expressed at high levels within the bone marrow in hematopoietic 
stem cells (HSCs). Mouse bone marrow cells isolated on the basis of EPCR expression alone 
are highly enriched HSCs, showing levels of engraftment in vivo comparable to that of stem 
cells purified using the most effective conventional methods (Balazs, 2006). Moreover, they 
showed that hematopoietic stem cell activity is always associated with EPCR-expressing 
cells (Balazs, 2006). In addition, high EPCR-expressing cells are observed in basal-like 
tumours in breast cancer (Park, 2010).  
EPCR does not mediate cell signalling, but acts as a homing receptor to allow APC to cleave 
PAR-1 (Riewald, 2002). The PARs are G-protein coupled receptors found on most cells. The 
four known PARs are activated via proteolytic cleavage by various proteases that results in 
an intra-molecular tethered ligand that triggers activation  of a G protein and subsequent 
intracellular signalling (Coughlin, 2000). Thrombin activates PAR-1, PAR-3, and PAR-4, 
whereas other serine proteases, including APC (Riewald, 2002). but not thrombin, activate 
PAR-2. Subsequent functional activity of APC cleavage of PAR-2 is yet to be fully 
elucidated, although our experiments indicate that APC acts through PAR-2 to promote 
wound healing in mice (Julovi et al, personal communication) . While the majority of 
reports cast PAR-2 as pro-inflammatory, others show that PAR-2 agonists are beneficial in 
several mouse models that involve inflammation or ischemia (Milia, 2002). Among the 
PARs, PAR-1 is most widely expressed and has been most extensively studied. APC 
bound to EPCR can activate PAR-1 and promote the anti-inflammatory and anti-apoptotic 
actions of APC (Riewald, 2002). 
Both thrombin and APC can cleave PAR-1 at identical locations. Thrombin cleavage causes 
platelet activation, increases vascular permeability, activates NF-B and elevates 
inflammatory cytokines, all of which promote an inflammatory response. Unexpectedly, 
when APC cleaves PAR-1, its actions are directly opposite to that of thrombin. APC strongly 
inhibits vascular permeability, activation of NF-B, endothelial adhesion molecule 
expression, cytokine production and monocyte migration (Riewald, 2002).  Studies using 
endothelial cells and other cell types show that when APC activates PAR-1 in an EPCR-
dependent manner, it causes alterations in gene expression profiles and exerts direct anti-
apoptotic effects (Guo, 2004; Joyce, 2001). However, compared to thrombin, APC is 
relatively inefficient and requires ~104 higher concentration (Kuliopulos, 1999) to cleave 
PAR-1. This has raised doubts about the possibility of APC having a physiological effect by 
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acting through PAR-1. Bae et al (Bae, 2007) have partially solved this issue by showing that 
APC cleaves PAR-1 on lipid rafts in endothelial cells. They subsequently identified a novel 
pathway whereby EPCR is associated with caveolin-1 in lipid rafts in endothelial cells (Bae, 
2007). These discrete, cholesterol and sphingolipid enriched microdomains of the cell 
membrane provide a protective compartment for APC to act in isolation. When APC 
binds to EPCR in the lipid raft, caveolin-1 is replaced with PAR-1 which couples with the 
pertussis toxin sensitive Gi-protein to initiate a protective signalling pathway. In contrast, 
when thrombin cleaves PAR-1 outside the lipid raft signalling occurs via Gq and/or 
G12/13 which exert inflammatory effects.  Interestingly, if EPCR is occupied on the lipid 
raft, even thrombin, can induce activation of the Gi protein and mimic the protective 
effects of APC (Bae, 2007).  
3.2 Epidermal growth factor receptor (EGFR) and Tie2 
In normal epidermis, EGFR is important for autocrine growth of this renewing tissue, 
suppression of terminal differentiation, promotion of cell survival, and regulation of cell 
migration during epidermal morphogenesis. In wounded skin, EGFR is momentarily up-  
 
 
Fig. 1. Proposed signal pathway for APC’s protective role on barrier function in confluent 
keratinocytes. APC binds to EPCR which cleaves PAR-1. G protein transactivates EGFR 
which may further transactivate Tie2 receptor, although the mechanism of activation is 
unclear. This triple receptor action results in increased ZO-1 and phosphorylation of Akt via 
PI3K and inhibition of ERK, leading to an increase in keratinocyte survival and barrier 
function. From (Xue, 2011). 
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regulated and is a major contributor to the proliferative and migratory aspects of wound re-
epithelialization. EGFR is able to regulate cell adhesion, expression of matrix degrading 
proteinases, and cell migration to provide a vital contribution to the migratory and invasive 
potential of keratinocytes (Hudson & McCawley, 1998). APC appears to act through EGFR 
to regulate  lymphocyte migration (Feistritzer, 2006) and wound healing (Xue, 2007). When 
keratinocytes are stimulated with APC, the expression and phosphorylation of EGFR is 
markedly increased and conversely when cells are treated with protein C siRNA, the 
phosphorylated form of EGFR in cell lysates is inhibited by more than 50% (Xue, 2007). 
Using dual immunofluorescent staining, we found that both EPCR and activated EGFR are 
co-localized in basal and suprabasal keratinocytes in the epidermis, which is identical to 
protein C localization in skin epidermis (Xue, 2007).  Furthermore, APC does not activate 
Tie2 through its major ligand, Ang-1, in keratinocytes, but instead acts by binding to EPCR, 
cleaving PAR-1 and trans-activating EGFR followed by transactivation of Tie2 (Figure 1). 
When activation of Akt, but not ERK, is inhibited, the barrier protective effect of APC on 
keratinocytes is abolished. Another report has indicated that, extracellularly, APC engages 
EPCR, PAR-1, and EGFR in order to increase the invasiveness of MDA-MB-231 cells 
(Gramling, 2010). 
3.3 Other receptors 
EPCR-independent signaling components of the APC pathway have been identified in 
monocytes. Apolipoprotein E receptor 2 (ApoER2) binding of APC results in 
phosphorylation of Dab1 and activation of the PI3K and Akt pathway resulting in decreased 
tissue factor release from monocytes (Yang, 2009).  
The efficacy of APC in murine endotoxemia is dependent on integrin CD11b. Genetic 
inactivation of CD11b, PAR1, or sphingosine kinase-1, but not EPCR, abolished the ability of 
APC to suppress the macrophage inflammatory response in vitro. Using a LPS-induced 
mouse model of lethal endotoxemia, Cao et al (Cao, 2010) showed that APC administration 
reduced the mortality of wild-type mice, but not CD11b-deficient mice. 
 
Receptor Significant Finding Year Reference 
Tie2 
APC increases angiopoietin to activate 
Tie2 in endothelial cells 
APC activates PAR-1 which 
transactivates Tie2 in keratinocytes
2010 
2011
(Minhas, 2010) 
(Xue, 2011) 
CD11b APC acts through Cd11b in 
macrophages
2009 (Cao, 2010) 
ApoER2 ApoER2 acts independent of EPCR and 
PAR-1 to phosphorylate Dab-1
2008 (Yang, 2009) 
EGFR APC phosphorylates EGFR in HUVEC 2005 (Montiel, 2005) 
PAR-3 Prevention of neuronal cell apoptosis 2004 (Guo, 2004) 
PAR-2 APC bound EPCR supports cleavage of 
PAR-2
2002 (Riewald, 2002) 
EPCR/PAR-1 APC bound EPCR cleaves PAR-1 
resulting in APCs effects
2002 (Riewald, 2002) 
Table 1. Cell receptors that APC acts through to exert its anti-inflammatory and 
cytoprotective effects. 
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3.4 Intracellular signaling 
The transcription factors, NF-B and the AP-1 complex, a transcriptionally active 
heterodimer of Fos and Jun proteins, regulate the expression of genes involved in immune 
and inflammatory responses. They play a pivotal role in the regulation of inflammation 
(Carmi & Razin, 2007). APC prevents activation of NF-B and AP-1 stimulated by LPS and 
endotoxin in human monocytes. The MAP kinase pathway is a prerequisite for growth 
factor stimulated mitogenesis in many cell types. Three major downstream MAP kinase 
cascades are mitogen- activated ERK1/2 and stress/cytokine-activated p38 and c-Jun N-
terminal kinases. APC induces cell proliferation via activation of the ERK1/2 pathway in 
endothelial cells (Uchiba, 2004). Similarly, stimulation of smooth muscle cells with APC 
induces a synergistic effect on ERK-1/2 phosphorylation and DNA synthesis (Bretschneider, 
2007). In human keratinocytes, blocking protein C expression or inhibiting its binding to 
EPCR/EGFR decreases the phosphorylation of ERK1/2 but increases p38 activation. 
Furthermore, inhibition of ERK completely abolishes APC’s stimulatory effect on 
proliferation. These results indicate that keratinocyte-derived protein C promotes cell 
growth in an autocrine manner via EPCR, EGFR and activation of ERK1/2 (Xue, 2007).  
Furthermore, when activation of Akt, but not ERK, is inhibited, the barrier protective effect 
of APC on keratinocytes is abolished. Thus, APC activates Tie2, which selectively enhances 
the PI3K/Akt signalling to stimulate junctional complexes and reduce keratinocyte 
permeability (Xue, 2011). 
4. APC in inflammatory disease 
APC has therapeutic benefit in a number of other diseases, through its anticoagulant, anti-
apoptotic, anti-inflammatory activities and positive effects on cell growth, migration and 
barrier stabilization, summarized in Figure 2. The following sections detail evidence for the 
potential beneficial effects of APC in a number of disorders associated with abnormal auto-
immune/inflammatory responses. 
4.1 Sepsis 
Severe sepsis is a very serious condition characterized physiologically by an aberrant 
systemic inflammatory response and microvascular dysfunction. Low levels of endogenous 
protein C provokes endotoxic (Levi, 2003) and septic responses (Ganopolsky & Castellino, 
2004). In human sepsis, there is a reduction in circulating  APC which appears to be due to 
both decreased levels of protein C, with  protein C levels strongly inversely correlating with 
sepsis prognosis (Fisher, Jr. & Yan, 2000) and decreased activation of protein C to APC 
(Liaw, 2004). Evidence from the PROWESS and ENHANCE clinical trials suggests that 
administration of recombinant human APC (drotrecogin alfa) reduces mortality in a subset 
of patients with severe sepsis (Bernard, 2004; Bernard, 2001; Marti-Carvajal, 2003).  It is 
indicated for use in patients with sepsis involving acute organ dysfunction who have a high 
risk of death. Two recent case reports provide evidence that APC may also be useful to treat 
multi-organ failure resulting from severe malaria (Kendrick, 2006; Srinivas, 2007). However, 
there is evidence that APC may cause bleeding in some patients, especially children and 
patients who have undergone recent surgery (Marti-Carvajal, 2007). The therapeutic effect 
and controversies of APC in severe sepsis has been extensively reviewed (Griffin, 2002; 
O'Brien, 2006; Short, 2006). Commercial preparations of recombinant APC (Xigris, Ely Lilly, 
Indianapolis) are readily available and FDA approved. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 52
Endogenous APC signaling is critical to protection of mice from LPS-induced septic shock 
(Xu, 2009). Many mechanisms have been described, but the exact manner in which APC 
affects sepsis patients is unclear. Therapeutic APC can regulate neutrophil migration and 
extravasation by direct engagement of ǃ1 and ǃ3 integrins (Elphick, 2009), suppress 
macrophage activation dependent on integrin CD11b/CD18 (Kerschen, 2010), control 
maturation and activation of CD8+ DCs dependent on EPCR (Kerschen, 2010), and 
neutralize late-stage inflammatory mediators by degrading nuclear histones from apoptotic 
cells (Xu, 2009).  
A recent Cochrane review suggested that APC should not be used for treating patients with 
severe sepsis or septic shock and that APC is associated with a higher risk of bleeding 
(Marti-Carvajal, 2011). Unless additional RCTs provide evidence of a treatment effect, 
policy-makers, clinicians and academics have been advised not promote the use of APC 
(Marti-Carvajal, 2011). Nonetheless, new reports continue to show that patients with septic 
shock who were treated with APC had a reduced in-hospital mortality compared with those 
not treated with APC (Sadaka, 2011). 
 
Fig. 2. The diverse biological effects of APC. APC exerts numerous molecular effects which 
lead to cellular responses which cause protective effects in a number of diseases. Ang= 
angiopoietin; EGFR= epidermal growth factor receptor; IL=interleukin; MMP=matrix 
metalloproteinase; TGF=transforming growth factor; TNF=tumour necrosis factor-ǂ; 
ZO=zona occludens; Bcl=B-cell lymphoma; BAX=Bcl-2–associated X protein.  
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4.2 Spinal cord injury (SCI)  
SCI can be induced by a physical insult resulting in an inflammatory response that leads to 
tissue destruction and life-long disabilities. Therapeutic intervention in SCI is largely being 
directed at reducing or alleviating inflammation (Okajima, 2004). In rat models, the 
inflammatory response occurs due to infiltration by neutrophils and release of TNF- 
(Taoka, 2000). Taoka et al (Taoka, 1997) demonstrated that a P-selectin mediated interaction 
between activated neutrophils and endothelial cells may be a critical step in endothelial cell 
damage leading to spinal cord injury in rats. These authors (Taoka, 1998) originally showed 
that rats subjected to compression-trauma induced SCI and treated with APC have a 
marked reduction in motor disturbances (Taoka, 1998), however, 12 years later this paper 
was retracted by the authors (2011). APC significantly reduces motor disturbances and 
micro-infarctions of the spinal cord in rats subjected to ischemia/reperfusion-induced SCI 
(Hirose, 2000). The increased tissue levels of TNF- and neutrophils in the injured part of 
the spinal cord were significantly reduced in animals that received APC. 
APC has direct neuroprotective effects, independent of its anticoagulant activity (Zlokovic, 
2005). In a rabbit model of ischemic spinal cord injury, APC eases the functional deficits and 
increases the number of motor neurons (Yamauchi, 2006). Interestingly, APC induces 
insulin-like growth factor (IGF)-1, IGF-1 receptor and the downstream p-Akt which might 
partially explain the neuroprotective effects of APC after transient spinal cord ischemia in 
rabbit. 
4.3 Brain injury and stroke 
Elevated plasma protein C levels are linked to a lower incidence of ischemic stroke in 
humans (Folsom, 1999) and conversely, lower circulating APC levels are found in patients 
with post-infection ischemic stroke compared to the control subjects (Macko, 1996). These 
data imply that the protein C pathway may protect against stroke. In a murine model of 
focal cerebral ischemia, APC significantly improved cerebral blood flow in the ischemic 
hemisphere and markedly reduced the volume of brain injury caused by middle cerebral 
vein occlusion. These effects were dependent on EPCR and PAR-1 and seemingly 
independent of APC’s anticoagulant effects  (Fernandez, 2003; Guo, 2004; Shibata, 2001). 
APC directly prevents apoptosis in hypoxic human brain endothelium through inhibition of 
p53, normalization of the pro-apoptotic Bax/Bcl-2 ratio, and reduction of caspase-3 
signalling (Guo, 2004). APC's cytoprotection of endothelial cells in vitro requires EPCR and 
PAR-1(Guo, 2004; Mosnier & Griffin, 2003).  APC can also directly protect perturbed 
neurons from cell injury and apoptosis. In vitro, APC reduces apoptosis in mouse cortical 
neurons treated with N-methyl-D-aspartate (NMDA) and staurosporine (Guo, 2004). 
Interestingly, PAR-1 and PAR-3 are required for this effect. Intra-cerebral APC infusion 
dose-dependently reduces NMDA excitotoxic injury in mice (Guo, 2004). Overall, APC 
maintains the patency of ischemic vasculature by inhibiting hypoxia-induced endothelial 
cell apoptosis and also directly protects the integrity and functionality of the neuronal 
network. 
Periventricular leukomalacia is the dominant form of brain injury in premature infants, 
characterized by white matter injury. The underlying pathogenic mechanisms include 
hypoperfusion, procoagulant activity, apoptotic cell death, microglial activation and 
inflammation associated with maternal and/or fetal infection (Genc, 2006). They 
hypothesized that APC, which modulates many of these processes, is a promising 
therapeutic agent for periventricular leukomalacia. 
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4.4 Alzheimer’s disease 
Alzheimer’s disease is characterized by elevated levels of amyloid ǃ peptide (Aǃ) in the 
brain that are associated with neuronal and vascular toxicity and is the major cause of 
dementia with advancing age. Inflammation, Aǃ deposition in the brain parenchyma and 
vessels, blood–brain barrier dysfunction, oxidative stress, formation of advanced end 
glycation products and endothelial and neural cell death have all been implicated in the 
pathogenesis of Alzheimer’s disease (Zlokovic, 2005). It has been proposed that APC could 
be useful in treating Alzheimer’s disease, since it has anti-inflammatory, anti-oxidant, 
profibrinolytic, neurovascular protectant and pro-angiogenic properties (Genc, 2007). 
Furthermore, APC exerts anti-inflammatory and anti-apoptotic activities directly on 
endothelial and neural cells (Griffin, 2006). APC protects against neurovascular injury in 
experimental stroke models, protects endothelial barrier integrity and decreases fibrin 
deposition (Griffin, 2006). Similar to its anti-inflammatory effect on other cells, APC may 
inhibit the activation status of the microglia that plays a key role in neuroinflammation.  
4.5 Acute kidney injury 
In a rat model of endotoxemia, rat APC significantly improved peritubular capillary flow 
and reduced leukocyte adhesion and rolling, 3 hours after treatment with LPS (Gupta, 2007). 
After 24 hr, APC treatment significantly improved renal blood flow. In addition, APC 
modulated the renin-angiotensin system by reducing mRNA expression levels of 
angiotensin converting enzyme-1, angiotensinogen in the kidney (Gupta, 2007). Thus, APC 
can suppress LPS-induced acute renal failure by modulating factors involved in vascular 
inflammation.  
Ischemia/reperfusion-induced renal injury is an important pathologic mechanism leading 
to acute renal failure (Thadhani, 1996).  In a rat model, intravenous administration of APC 
markedly reduces ischemia/reperfusion -induced renal dysfunction and tubular necrosis, 
whereas heparin or inactive APC has no effect (Mizutani, 2000). Furthermore, APC 
significantly inhibited the ischemia/reperfusion -induced decrease in renal tissue blood 
flow, the increase in the vascular permeability, and renal levels of TNF-, IL-8, and 
myeloperoxidase. Leukocytopenia produced effects similar to those of APC. These findings 
strongly suggested that APC has a protective effect against ischemia/reperfusion-induced 
renal injury by inhibiting activation of leukocytes rather than inhibiting coagulation 
(Okajima, 2004). Recently, Isemann et al (Isermann, 2007) have shown that APC protects 
against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.  In a rat 
model of sepsis by cecal ligation and puncture (CLP), treatment with APC significantly 
inhibited sepsis-induced elevations in creatinine, LDH levels, and improved renal 
architecture. Furthermore, sepsis-induced inhibition of interferon (INF)-Ǆ and increase in IL-
1ǃ and IL-10 were attenuated by APC treatment. The authors suggested that APC confers a 
survival advantage by reducing systemic inflammation and, in doing so, preserves organ 
function (Keller, 2011). 
4.6 Lung disorders 
In a mouse model of acute lung injury, APC inhalation attenuates LPS-induced 
amplification of neutrophils and macrophages in bronchoalveolar lavage fluid as well as 
VCAM-1 protein levels in lung tissue (Kotanidou, 2006). In a murine model of asthma, 
inhalation of APC significantly inhibits the expression of T helper 2 (Th2) cytokines, IgE, 
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eosinophilic inflammation, and hyper-responsiveness in bronchiolar lavage fluid (Yuda, 
2004). Electromobility shift assays show that translation of signal transducer and activator of 
transcription 6 (STAT6) and NF-B to the nucleus is reduced in lung samples from mice 
treated with inhaled APC. Although APC is thought to have a short half-life of ~ 20 mins, it 
can be detected in mice bronchoalveolar lavage fluid 24 h after inhalation. Thus, APC 
inhalation might offer a long-acting alternative route of administration to the lungs to 
attenuate pulmonary inflammation in acute lung injury.  
It is unclear whether APC has any beneficial effect in humans with inflammatory lung 
diseases. Nick et al (Nick, 2004) performed a double-blinded, placebo-controlled study of 
APC in a human model of endotoxin-induced pulmonary inflammation and showed that 
APC significantly reduced leukocyte accumulation to the airspaces, independent of 
pulmonary cytokine or chemokine release. Bronchoalveolar lavage fluid neutrophils of 
patients receiving APC demonstrated decreased chemotaxis ex vivo but no change in 
cytokine release, cell survival, or apoptosis. The major components of the protein C 
pathway, including thrombomodulin, protein C and EPCR are all expressed by human 
airway epithelial cells (Hataji, 2002). Activation of protein C is reduced in sputum of 
patients with bronchial asthma compared to control subjects, which may contribute to 
exacerbation of the inflammatory response in the airway of asthmatic patients  (Hataji, 
2002). However, Schouten et al (Schouten, 2011) showed that endogenous protein C has 
strong effects on the host response to lethal influenza A infection, on the one hand inhibiting 
pulmonary coagulopathy and inflammation, but on the other hand facilitating neutrophil 
influx and protein leak and accelerating mortality. 
4.7 Acute pancreatitis 
Acute pancreatitis is a local inflammatory process that leads to a systemic inflammatory 
response and multiple organ failure (Kirschenbaum & Astiz, 2005). Disseminated 
intravascular coagulation and thromboembolism are related to overall morbidity of this 
disease which provides a setting in which APC could play a therapeutic role. Ottesen et al 
(Ottesen, 1999) found  a decrease in levels of protein C in animals with acute pancreatitis. In 
a rodent model of pancreatitis (Alsfasser, 2006), treatment with APC reduces inflammation 
in the pancreas and lungs and significantly improves survival compared to controls (86% vs 
38%; P=.05). This animal model exhibits severe consumptive coagulopathy, however APC’s 
anti-coagulation properties did not worsen this condition. In another study, when APC was 
given 6 hours after the induction of pancreatitis, it significantly reduced acinar necrosis, 
tissue edema, fat necrosis, IL-6 and TNF-ǂ and inflammatory infiltration compared to 
controls. Inhibition of expression of pancreatic p38 MAPK and JNK and upregulation of 
ERK1/2 expression by APC treatment protects against pancreatic injury, thus ameliorating 
severity of the disease (Chen, 2007).  
4.8 Type 1 Diabetes (T1D) 
T1D is a chronic progressive autoimmune disease that affects genetically prone individuals. 
The physiological destruction of -cells is a crucial event for disease onset (Mathis, 2001). 
Inflammation and auto-immunity play an important role in the destruction of pancreatic 
islet -cells in T1D, with apoptosis being the dominant form of -cell death in both animal 
models of diabetes and humans. Replacement of the -cells by transplantation of islet cells is 
a radical therapy for human T1D. A major problem with this therapy is the large loss of 
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viability of islet cells during the procedure. APC’s strong anti-inflammatory and anti-
apoptotic properties appear to be beneficial in preventing destruction of islet cells. 
Exogenous administration of APC significantly reduces loss of functional islet mass after 
intraportal transplantation in diabetic mice (Contreras, 2004). Animals given APC exhibit 
better glucose control, higher glucose disposal rates and higher arginine-stimulated acute 
insulin release (Contreras, 2004). These effects are associated with a reduction in plasma 
proinsulin, intrahepatic fibrin deposition, and islet apoptosis early after the transplant. APC 
treatment is also associated with a significant reduction of proinflammatory cytokine release 
and prevents endothelial cell activation and dysfunction. This study suggests that APC 
therapy will improve the take-rate of the transplanted islet cells and thus decrease the 
number of the  cells required for human pancreatic islet transplantation (Contreras, 2004).  
Interestingly, plasma levels of protein C/APC are reduced in humans with T1D (Gruden, 
1997; Vukovich & Schernthaner, 1986). In addition, soluble EPCR, which binds to APC 
and inhibits its activity, is increased in T1D (Wu, 2000). These data together indicate that 
circulating APC activity is markedly reduced in T1D. Whether replenishment of APC 
levels will benefit patients with T1D is yet to be resolved. However, APC exhibits great 
potential in preventing glucose-induced apoptosis in endothelial cells and podocytes 
(Isermann, 2007). 
4.9 Rheumatoid Arthritis (RA) 
RA is a chronic autoimmune disease characterized by persistent inflammation of multiple 
synovial joints which results in progressive tissue destruction of bone and cartilage. Protein 
C/APC is present in RA synovial tissues and co-localizes with MMP-2 in endothelial and 
synovial lining cells (Buisson-Legendre, 2004). EPCR is also strongly expressed by synovial 
tissue in patients with RA and co-localizes with CD68 positive staining cells, indicating that 
these cells are largely macrophage/monocytes (Xue, 2007). Inhibiting the activation of 
monocytes/macrophages reduces the severity of arthritis in patients with RA and in animal 
models of RA (Bondeson, 1999; Kwasny-Krochin, 2002). APC inhibits activation of normal 
monocytes by preventing their migration and production of proinflammatory 
cytokines/chemokines, such as TNF- and macrophage migration inhibitory factor levels 
(Schmidt-Supprian, 2000). When monocytes from RA patients are pre-treated with APC, 
their migration towards monocyte chemoattractant protein-1 (MCP-1) is inhibited in a dose-
dependent manner (Xue, 2007). Pre-incubation of these cells with RCR252, an antibody 
which blocks APC binding to EPCR, abolishes this inhibitory effect of APC, indicating that 
APC acts through EPCR to inhibit the chemotactic response of RA monocytes.  MMP-9 
regulation may be at least one downstream effector of APC’s inhibition of monocyte 
migration. When added to purified monocytes from RA patients, APC dose-dependently 
inhibits the production of MMP-9 (Xue, 2007). MMP-9 not only allows cell migration but 
also exerts direct pro-inflammatory effects, such as activation of cytokines which would 
enhance the beneficial effect of APC in RA.  
NF-B is activated in synovium from RA patients (Marok, 1996) and in cultured RA 
synovial fibroblasts (Fujisawa, 1996). Inhibition of NF-B activity strongly reduces the 
severity of disease in animal models of arthritis by inhibiting leukocyte infiltration 
(Blackwell, 2004). High levels of NF-B activity are present in RA monocytes under basal 
conditions. APC (20 g/ml) dramatically inhibits the active form of NF-B in both control 
and LPS stimulated monocytes from RA patients. Downstream of NF-B is one of the most 
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potent inflammatory cytokines in RA, TNF- (Xue, 2007). Specific inhibition of TNF- 
using biological agents such as the monoclonal antibody, Adalimumab (marketed as 
Humira), is proving very successful in treating moderate to severe RA in adults who have 
had a poor response to other anti-rheumatic drugs. Monocytes/macrophages are the 
primary source of TNF- which, after release, promotes the proinflammatory activity of 
these and other surrounding cells. APC significantly decreases TNF- both in control and 
LPS-stimulated RA monocytes (Xue, 2007). Thus, APC may mimic the action of the 
“biological” agents, through inhibition of TNF-. However, by acting on multiple targets, 
APC may be more effective. 
4.10 Cancer  
APC can activate signaling molecules to promote MDA-MB-231 breast cancer cell and 
endothelial cell motility (Gramling, 2010). However, accumulating evidence suggests that 
the APC pathway limits cancer progression. Acquired protein C deficiency is observed in 
cancer patients, especially in patients using certain types of chemotherapy (Feffer, 1989; 
Mewhort-Buist, 2008; Rogers, 1988; Woodley-Cook, 2006).  The  loss of expression of 
thrombomodulin (or increase in its soluble form), a receptor required to convert protein C to 
APC, on cancer cells correlates with advanced stage and poor prognosis (Hanly, 2006; Hanly 
& Winter, 2007; Lindahl, 1993). Low levels of thrombomodulin also increase the invasive 
ability of cancer cells in vitro (Matsushita, 1998) and is significantly correlated with a high 
relapse rate in breast cancer (Kim, 1997). It is likely that low thrombomodulin levels induce 
metastasis due to reduced endogenous APC levels, although several alternative mechanisms 
have also been proposed (Hanly & Winter, 2007). Additionally, EPCR, the specific receptor 
for APC is detected in several cell lines derived from various types of cancer (Van Sluis, 
2010). For example, EPCR is expressed on human breast cancer cells, with an extremely high 
frequency (Tsuneyoshi, 2001). EPCR on the vascular wall inhibits cancer cell adhesion and 
transmigration (Bezuhly, 2009; Lindahl, 1993). Finally, significant resistance to APC was 
found in women with a lymph-node-positive breast carcinoma (Bezuhly, 2009; Lindahl, 
1993; Nijziel, 2003). In a mouse model, endogenous APC has been found to limit cancer cell 
extravasation via sphingosine-1-phosphate receptor-1 and VE-cadherin-dependent vascular 
barrier enhancement. Van Sluis et al (Van Sluis, 2011) showed that in the absence of 
endogenous APC, fibrinogen depletion does not prevent cancer cell dissemination and 
secondary tumor formation in immune-competent mice. Overall, they show that 
endogenous APC is essential for immune-mediated cancer cell elimination (Van Sluis, 2011). 
The exact mechanisms on how about prevents cancer are not clear. However, recently, a 
number of studies have shown that activation of PAR1 are involved in limiting of tumour 
cell migration and  invasion/metastasis in vitro and in vivo (Kamath, 2001; Nierodzik, 1998; 
Villares, 2011) and intact barrier function can effectively prevent tumour cell migration and  
metastasis. APC can enhance both endothelial and epithelial barrier functions via activation 
of PAR1 which may partly explain the underlying mechanisms(Minhas, 2010; Xue, 2011). 
4.11 Skin injuries 
Chronic wounds are a common health problem. There are many different factors which lead 
to a chronic wound, including advancing age, persistent inflammatory stimuli, tissue 
hypoxia, diabetes mellitus, immunodeficiency, a smoking history or the use of certain 
medications, but they can affect patients at any race or economic background. The common 
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types of chronic wounds include: peripheral ulcers, which are the most frequent cause of 
lower limb amputation in patients with type I and type II diabetes (Levin, 1993); decubitus 
ulcers, a result of prolonged, unrelieved pressure over a bony prominence and venous stasis 
ulcers, where venous congestion of the lower extremities results in local hypoxia (Trent, 
2005).  With the current diabetes epidemic and increasing aging population, chronic wounds 
are a serious concern to the health system. They require dedicated care including regular 
dressings, frequent clinic appointments and when complications arise, hospital admission 
potentially requiring surgery or even amputation. The “state-of-the-art” treatments for 
chronic wounds are expensive and have limited success. Cutaneous wound repair can be 
divided into a series of overlapping phases including formation of fibrin clot, inflammatory 
response, granulation tissue formation, which includes re-epithelialization and 
angiogenesis, and matrix remodeling. Re-epithelialization is an important component of 
wound repair as it serves to restore the barrier function of skin. Newly formed blood vessels 
provide nutrition and oxygen to the growing tissue and allow leukocytes to enter the site of 
injury. A chronic wound or ulcer occurs when the co-coordinated cellular and biochemical 
response to injury are disrupted.  
 
 
Fig. 3. APC treatment used in conjunction with topical negative pressure (TNP) to treat a 
recalcitrant orthopaedic wound present for 2 years. APC and TNP were applied on day 0 
and twice a week until day 19. Day 0 shows exposed bone (arrow) and day 7 shows healthy 
granulation tissue covering bone. Wound is fully healed by day 28 and remained healed at 8 
months follow-up. Taken from Wijewardana et al, Int J Lower Extrem Wounds in press, 
2011. 
The role of inflammation in wound healing is under debate. Many researchers believe that 
the inflammatory phase is vital for wound healing to proceed, however, there is evidence to 
suggest otherwise. Whereas normal adult healing results in a fibrous scar, early fetal 
wounds which have very little, if any, inflammatory response, exhibit scarless healing with 
complete restoration of the normal skin architecture. Scar formation exacerbates when 
inflammation is provoked in fetal wounds, suggesting that the absence of inflammation 
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contributes to the rapid and flawless repair of these wounds (Szpaderska & DiPietro, 2005). 
Compared to dermal wounds, oral wounds have substantially lower levels of macrophage, 
neutrophil, and T-cell infiltration and heal rapidly with minimal inflammation and often 
with minimal scar formation (Szpaderska, 2003). Redd et al  (Redd, 2004) studied wound 
healing in the PU.1 null mouse, which is genetically incapable of raising an inflammatory 
response because several haematopoietic lineages, including macrophages and 
neutrophils, are absent or severely delayed in their differentiation. Wounds in these 
animals rapidly repair with increased vascularity at the wound site and faster 
reepithelialisation of the wound surface, as well as being scarless (Redd, 2004). They 
hypothesised that the lower the level of some growth factors in adult wounds the closer it 
would mimic scar-free healing in the embryo. This is relevant to many chronic wounds 
which are often associated with excess inflammation and become locked in this 
inflammatory phase. Thus, APC’s anti-inflammatory effects may actually benefit, rather 
than hinder, the healing of chronic wounds. 
Keratinocytes and endothelial cells are two major cell types in skin and play critical roles in 
the healing of skin injury. Keratinocytes of the epidermis provide the major cellular 
component of the outermost barrier to the environment. When the skin is broken, a critical 
response is triggered to restore its protective function. Within 24 hours of wounding, 
keratinocytes from the wound margins begin to migrate and invade the wound bed, where 
they proliferate to form the new epithelium. We have shown that protein C is produced by 
skin keratinocytes, especially those in the basal layer (Xue, 2007). This endogenous protein C 
is activated on the cell surface, with the resulting APC stimulating a wound healing 
phenotype in keratinocytes (Xue, 2005; Xue, 2007). Furthermore, the autocrine actions of 
APC are necessary for normal keratinocyte growth and function (Xue, 2007).  APC 
stimulates proliferation, MMP-2 activity, migration and prevents apoptosis in skin 
keratinocytes, all vital processes of re-epithelialization (Xue, 2005; Xue, 2004). Endothelial 
migration and proliferation are vital to generate new blood vessels for wound healing. APC 
stimulates endothelial cell proliferation and induces tube-like structure formation in vitro 
(Uchiba, 2004) and cell migration (Brueckmann, 2003). In the chick chorioallantoic 
membrane (CAM) assay, APC stimulates angiogenesis and re-epithelialization. In vivo, APC 
induces corneal angiogenesis in a mouse model (Uchiba, 2004). APC also stimulates the 
proliferation of smooth muscle cells (Bretschneider, 2007), which would contribute to the 
formation of mature blood vessels.  In a full-thickness rat skin-healing model, a single 
topical application of APC enhances wound healing compared to saline control at least 
partly via stimulating angiogenesis and re-epithelialisation (Jackson, 2005). 
Recent evidence suggests that APC will be effective in humans with chronic wounds. An 
open label pilot study was conducted on 4 patients whose wounds were not improving, 
despite standard wound treatment for 4 months or greater (Whitmont, 2008). APC was 
applied topically to wounds once weekly for 4 weeks. All 4 patients showed rapid positive 
response to treatment which was maintained during a 4 month follow-up period. Overall, 
there was more than 80% reduction in wound size. The treatment was well tolerated with no 
significant side effects or complications experienced. In another recent study, APC treatment 
was used in conjunction with topical negative pressure (TNP), to treat recalcitrant long-
standing orthopaedic wounds (Wijewardana et al, Combination of activated protein C and 
topical negative pressure vacuum therapy rapidly regenerates granulation tissue over 
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exposed bone to heal recalcitrant orthopaedic wounds, in press, 2011, Int J Lower Extrem 
Wounds). One example is a 47 year old male with no significant co-morbidities who had 
tibial and fibula fractures following an assault and being hit in the leg by a baseball bat, 2 
years prior to presentation. The fractures required open reduction and fixation with plates 
and screws. Two months post-operatively he developed an infection and breakdown of the 
wound. He was started on antibiotic treatment and had wash out of the wound and 
scraping of the bone which showed osteomyelitis. Antibiotic treatment was continued but 
failed to control the infection so all metal-ware was removed and the wound was debrided. 
There was malunion of the bone and after 3 months the plates and screws were replaced 
and the wound was covered with a fasciocutaneous flap. After one month, he again 
developed infection and breakdown of the flap. For the following year he had continued 
treatment with antibiotics, conventional and TNP dressings, however the wound remained 
non-healing. He was then treated with APC plus topical negative pressure and after 7 days a 
layer of healthy granulation tissue covered the bone and almost filled the entire wound 
space (Figure 3). By day 10 re-epithelialization had occurred on top of the dermis around the 
perimeter of the wound and by day 19 the wound had completely healed. Follow up at 8 
month showed the wound had continued to remain intact 
By dampening inflammation and accelerating angiogenesis and re-epithellialisation, APC 
is also likely to minimize scar formation, which holds great potential for burn victims and 
those susceptible to keloid scarring. Patients with burn injuries and inhalation trauma 
have a significant increase in thrombin generation in the airways compared with control 
patients, as reflected by increased lavage fluid levels of thrombin-antithrombin complexes 
and fibrin degradation products, and decreased lavage fluid levels of APC and 
antithrombin (Hofstra, 2011).  
5. Engineered protein C/APC 
The stereospecific interactions of APC with factors Va and VIIIa involve both the APC 
enzymatic active-site region and residues that are not part of the immediate APC active site. 
These residues are termed ‘exosites’ on the APC active enzyme surface and can be mutated 
to diminish the anticoagulant activity of APC without altering the cell-signaling activity of 
the molecule (Bae, 2007; Gale, 2002; Kerschen, 2007; Mosnier, 2004). Replacement of a cluster 
of five positively charged residues by alanine residues (ie. 5A-APC) on the top surface of the 
APC heavy-chain protease domain restructures this crucial positively charged exosite, 
causing >98% loss of the anticoagulant activity of human APC while leaving intact APC cell-
signaling activities on different cell types within the neurovascular unit (Mosnier, 2007; 
Mosnier, 2009). Replacement of three of these five residues (i.e. lysine residues 191–193) by 
three alanine residues produces the 3K3A-APC variant  (Deane, 2009; Guo, 2009; Wang, 
2009) which has a similar effect to the 5A-APC variant, causing loss of >92% of APC 
anticoagulant activity. These engineered variants provide APC for therapeutic purposes in 
which the risk of serious bleeding caused by the anticoagulant activity of APC is diminished 
while the cytoprotective effects of APC are preserved. In preclinical animal models of ALS 
(Zhong, 2009), stroke (Guo, 2009; Wang, 2009), brain injury (Walker, 2010) and sepsis 
{Kerschen, 2007 KERSCHEN2007 /id} and cytoprotective function (Ni, 2011) these APC 
variants show beneficial effects that were equivalent to, or sometimes greater than, the wild-
type recombinant APC. Bir et al (Bir, 2011) demonstrated that 5A-APC could attenuate lung 
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damage caused by P. aeruginosa in critically ill patients. In addition, 5A-APC inhibits the 
inflammatory response of conventional dendritic cells independent of EPCR and suppresses 
IFN-gamma production by natural killer-like dendritic cells (Kerschen, 2010).  Recently, an 
APC variant (APC-L38D/N329Q) was generated with minimal anticoagulant activity, but 5-
fold enhanced endothelial barrier protective function and 30-fold improved anti-apoptotic 
function when compared with wild type APC (Ni, 2011).  
An APC variant with minimal cell-signaling activity but with substantially increased 
anticoagulant activity, E149A-APC, has been useful for proof of concept studies and for 
antithrombotic indications (Mosnier, 2009). E149A-APC has superior antithrombotic activity 
in a mouse model of arterial thrombosis compared to wt-APC, but has no benefit in an 
endotoxemia sepsis model where wild type (wt)-APC or the 5A-APC variant reduced 
mortality {Kerschen, 2007 KERSCHEN2007 /id} (Mosnier, 2009). 
6. Conclusion 
APC, an anticoagulant with anti-inflammatory, anti-apoptotic, proliferative and barrier 
stabilization properties, has not only emerged as a therapeutic agent for use in selected 
patients with severe sepsis, but also appears to have considerable benefit in chronic wounds 
and a number of other autoimmune/inflammatory diseases. The in vitro, preclinical and 
limited clinical data for these diseases indicate that APC holds a remarkable promise. 
Further insights into the mechanisms of action of APC will be required for the translation of 
preclinical study results to the bedside. 
More than three decades since the discovery of APC, we are only beginning to learn of its 
biological diversity. The clinical evidence for APC as a treatment for severe sepsis is 
perplexing (Marti-Carvajal, 2007; Marti-Carvajal, 2011). Strong evidence indicates that APC 
will benefit other disorders involving various organ injuries including kidney injury, spinal 
cord injury, respiratory function and stroke. Blinded and controlled clinical trials will 
elucidate its clinical protective effects in these disorders. With the recent discovery that the 
largest organ of the body, the skin, positively responds to APC, it is likely that APC will 
accelerate healing of skin injuries and disorders.    
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